A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics

Ozhan Ocal, Victor Pashkov, Rahul K. Kollipara, Yalda Zolghadri, Victoria H. Cruz, Michael A. Hale, Blake R. Heath, Alex B. Artyukhin, Alana L. Christie, Pantelis Tsoulfas, James B. Lorens, Galvin H. Swift, Rolf A. Brekken, Thomas M. Wilkie

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer-related deaths in the United States, and is projected to be second by 2025. It has the worst survival rate among all major cancers. Two pressing needs for extending life expectancy of affected individuals are the development of new approaches to identify improved therapeutics, addressed herein, and the identification of early markers. PDA advances through a complex series of intercellular and physiological interactions that drive cancer progression in response to organ stress, organ failure, malnutrition, and infiltrating immune and stromal cells. Candidate drugs identified in organ culture or cell-based screens must be validated in preclinical models such as KIC (p48Cre;LSL-KrasG12D;Cdkn2af/f) mice, a genetically engineered model of PDA in which large aggressive tumors develop by 4 weeks of age. We report a rapid, systematic and robust in vivo screen for effective drug combinations to treat Kras-dependent PDA. Kras mutations occur early in tumor progression in over 90% of human PDA cases. Protein kinase and G-protein coupled receptor (GPCR) signaling activates Kras. Regulators of G-protein signaling (RGS) proteins are coincidence detectors that can be induced by multiple inputs to feedback-regulate GPCR signaling. We crossed Rgs16::GFP bacterial artificial chromosome (BAC) transgenic mice with KIC mice and show that the Rgs16::GFP transgene is a KrasG12D-dependent marker of all stages of PDA, and increases proportionally to tumor burden in KIC mice. RNA sequencing (RNA-Seq) analysis of cultured primary PDA cells reveals characteristics of embryonic progenitors of pancreatic ducts and endocrine cells, and extraordinarily high expression of the receptor tyrosine kinase Axl, an emerging cancer drug target. In proof-of-principle drugscreens, we find that we anling KIC mice with PDA treated for 2 weeks with gemcitabine (with or without Abraxane) plus inhibitors of Axl signaling (warfarin and BGB324) have fewer tumor initiation sites and reduced tumor size compared with the standard-of-care treatment. Rgs16::GFP is therefore an in vivo reporter of PDA progression and sensitivity to new chemotherapeutic drug regimens such as Axl-targeted agents. This screening strategy can potentially be applied to identify improved therapeutics for other cancers.

Original languageEnglish (US)
Pages (from-to)1201-1211
Number of pages11
JournalDMM Disease Models and Mechanisms
Volume8
Issue number10
DOIs
StatePublished - Oct 1 2015

Fingerprint

Tumors
Adenocarcinoma
Neoplasms
gemcitabine
G-Protein-Coupled Receptors
RGS Proteins
Pharmaceutical Preparations
Therapeutics
Cyclic GMP-Dependent Protein Kinases
Warfarin
Drug Combinations
Chromosomes
Ducts
Screening
RNA Sequence Analysis
Cells
Bacterial Artificial Chromosomes
RNA
Detectors
Feedback

Keywords

  • Abraxane
  • Axl
  • Gas6
  • Gemcitabine
  • Kras
  • Pancreatic cancer combination therapy
  • Rapid in vivo screen
  • Rgs16::GFP reporter
  • Warfarin

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine (miscellaneous)
  • Immunology and Microbiology (miscellaneous)
  • Neuroscience (miscellaneous)

Cite this

Ocal, O., Pashkov, V., Kollipara, R. K., Zolghadri, Y., Cruz, V. H., Hale, M. A., ... Wilkie, T. M. (2015). A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics. DMM Disease Models and Mechanisms, 8(10), 1201-1211. https://doi.org/10.1242/dmm.020933

A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics. / Ocal, Ozhan; Pashkov, Victor; Kollipara, Rahul K.; Zolghadri, Yalda; Cruz, Victoria H.; Hale, Michael A.; Heath, Blake R.; Artyukhin, Alex B.; Christie, Alana L.; Tsoulfas, Pantelis; Lorens, James B.; Swift, Galvin H.; Brekken, Rolf A.; Wilkie, Thomas M.

In: DMM Disease Models and Mechanisms, Vol. 8, No. 10, 01.10.2015, p. 1201-1211.

Research output: Contribution to journalArticle

Ocal, O, Pashkov, V, Kollipara, RK, Zolghadri, Y, Cruz, VH, Hale, MA, Heath, BR, Artyukhin, AB, Christie, AL, Tsoulfas, P, Lorens, JB, Swift, GH, Brekken, RA & Wilkie, TM 2015, 'A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics', DMM Disease Models and Mechanisms, vol. 8, no. 10, pp. 1201-1211. https://doi.org/10.1242/dmm.020933
Ocal O, Pashkov V, Kollipara RK, Zolghadri Y, Cruz VH, Hale MA et al. A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics. DMM Disease Models and Mechanisms. 2015 Oct 1;8(10):1201-1211. https://doi.org/10.1242/dmm.020933
Ocal, Ozhan ; Pashkov, Victor ; Kollipara, Rahul K. ; Zolghadri, Yalda ; Cruz, Victoria H. ; Hale, Michael A. ; Heath, Blake R. ; Artyukhin, Alex B. ; Christie, Alana L. ; Tsoulfas, Pantelis ; Lorens, James B. ; Swift, Galvin H. ; Brekken, Rolf A. ; Wilkie, Thomas M. / A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics. In: DMM Disease Models and Mechanisms. 2015 ; Vol. 8, No. 10. pp. 1201-1211.
@article{d82142e50fb54563b3bae6320c87d2aa,
title = "A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics",
abstract = "Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer-related deaths in the United States, and is projected to be second by 2025. It has the worst survival rate among all major cancers. Two pressing needs for extending life expectancy of affected individuals are the development of new approaches to identify improved therapeutics, addressed herein, and the identification of early markers. PDA advances through a complex series of intercellular and physiological interactions that drive cancer progression in response to organ stress, organ failure, malnutrition, and infiltrating immune and stromal cells. Candidate drugs identified in organ culture or cell-based screens must be validated in preclinical models such as KIC (p48Cre;LSL-KrasG12D;Cdkn2af/f) mice, a genetically engineered model of PDA in which large aggressive tumors develop by 4 weeks of age. We report a rapid, systematic and robust in vivo screen for effective drug combinations to treat Kras-dependent PDA. Kras mutations occur early in tumor progression in over 90{\%} of human PDA cases. Protein kinase and G-protein coupled receptor (GPCR) signaling activates Kras. Regulators of G-protein signaling (RGS) proteins are coincidence detectors that can be induced by multiple inputs to feedback-regulate GPCR signaling. We crossed Rgs16::GFP bacterial artificial chromosome (BAC) transgenic mice with KIC mice and show that the Rgs16::GFP transgene is a KrasG12D-dependent marker of all stages of PDA, and increases proportionally to tumor burden in KIC mice. RNA sequencing (RNA-Seq) analysis of cultured primary PDA cells reveals characteristics of embryonic progenitors of pancreatic ducts and endocrine cells, and extraordinarily high expression of the receptor tyrosine kinase Axl, an emerging cancer drug target. In proof-of-principle drugscreens, we find that we anling KIC mice with PDA treated for 2 weeks with gemcitabine (with or without Abraxane) plus inhibitors of Axl signaling (warfarin and BGB324) have fewer tumor initiation sites and reduced tumor size compared with the standard-of-care treatment. Rgs16::GFP is therefore an in vivo reporter of PDA progression and sensitivity to new chemotherapeutic drug regimens such as Axl-targeted agents. This screening strategy can potentially be applied to identify improved therapeutics for other cancers.",
keywords = "Abraxane, Axl, Gas6, Gemcitabine, Kras, Pancreatic cancer combination therapy, Rapid in vivo screen, Rgs16::GFP reporter, Warfarin",
author = "Ozhan Ocal and Victor Pashkov and Kollipara, {Rahul K.} and Yalda Zolghadri and Cruz, {Victoria H.} and Hale, {Michael A.} and Heath, {Blake R.} and Artyukhin, {Alex B.} and Christie, {Alana L.} and Pantelis Tsoulfas and Lorens, {James B.} and Swift, {Galvin H.} and Brekken, {Rolf A.} and Wilkie, {Thomas M.}",
year = "2015",
month = "10",
day = "1",
doi = "10.1242/dmm.020933",
language = "English (US)",
volume = "8",
pages = "1201--1211",
journal = "DMM Disease Models and Mechanisms",
issn = "1754-8403",
publisher = "Company of Biologists Ltd",
number = "10",

}

TY - JOUR

T1 - A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics

AU - Ocal, Ozhan

AU - Pashkov, Victor

AU - Kollipara, Rahul K.

AU - Zolghadri, Yalda

AU - Cruz, Victoria H.

AU - Hale, Michael A.

AU - Heath, Blake R.

AU - Artyukhin, Alex B.

AU - Christie, Alana L.

AU - Tsoulfas, Pantelis

AU - Lorens, James B.

AU - Swift, Galvin H.

AU - Brekken, Rolf A.

AU - Wilkie, Thomas M.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer-related deaths in the United States, and is projected to be second by 2025. It has the worst survival rate among all major cancers. Two pressing needs for extending life expectancy of affected individuals are the development of new approaches to identify improved therapeutics, addressed herein, and the identification of early markers. PDA advances through a complex series of intercellular and physiological interactions that drive cancer progression in response to organ stress, organ failure, malnutrition, and infiltrating immune and stromal cells. Candidate drugs identified in organ culture or cell-based screens must be validated in preclinical models such as KIC (p48Cre;LSL-KrasG12D;Cdkn2af/f) mice, a genetically engineered model of PDA in which large aggressive tumors develop by 4 weeks of age. We report a rapid, systematic and robust in vivo screen for effective drug combinations to treat Kras-dependent PDA. Kras mutations occur early in tumor progression in over 90% of human PDA cases. Protein kinase and G-protein coupled receptor (GPCR) signaling activates Kras. Regulators of G-protein signaling (RGS) proteins are coincidence detectors that can be induced by multiple inputs to feedback-regulate GPCR signaling. We crossed Rgs16::GFP bacterial artificial chromosome (BAC) transgenic mice with KIC mice and show that the Rgs16::GFP transgene is a KrasG12D-dependent marker of all stages of PDA, and increases proportionally to tumor burden in KIC mice. RNA sequencing (RNA-Seq) analysis of cultured primary PDA cells reveals characteristics of embryonic progenitors of pancreatic ducts and endocrine cells, and extraordinarily high expression of the receptor tyrosine kinase Axl, an emerging cancer drug target. In proof-of-principle drugscreens, we find that we anling KIC mice with PDA treated for 2 weeks with gemcitabine (with or without Abraxane) plus inhibitors of Axl signaling (warfarin and BGB324) have fewer tumor initiation sites and reduced tumor size compared with the standard-of-care treatment. Rgs16::GFP is therefore an in vivo reporter of PDA progression and sensitivity to new chemotherapeutic drug regimens such as Axl-targeted agents. This screening strategy can potentially be applied to identify improved therapeutics for other cancers.

AB - Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer-related deaths in the United States, and is projected to be second by 2025. It has the worst survival rate among all major cancers. Two pressing needs for extending life expectancy of affected individuals are the development of new approaches to identify improved therapeutics, addressed herein, and the identification of early markers. PDA advances through a complex series of intercellular and physiological interactions that drive cancer progression in response to organ stress, organ failure, malnutrition, and infiltrating immune and stromal cells. Candidate drugs identified in organ culture or cell-based screens must be validated in preclinical models such as KIC (p48Cre;LSL-KrasG12D;Cdkn2af/f) mice, a genetically engineered model of PDA in which large aggressive tumors develop by 4 weeks of age. We report a rapid, systematic and robust in vivo screen for effective drug combinations to treat Kras-dependent PDA. Kras mutations occur early in tumor progression in over 90% of human PDA cases. Protein kinase and G-protein coupled receptor (GPCR) signaling activates Kras. Regulators of G-protein signaling (RGS) proteins are coincidence detectors that can be induced by multiple inputs to feedback-regulate GPCR signaling. We crossed Rgs16::GFP bacterial artificial chromosome (BAC) transgenic mice with KIC mice and show that the Rgs16::GFP transgene is a KrasG12D-dependent marker of all stages of PDA, and increases proportionally to tumor burden in KIC mice. RNA sequencing (RNA-Seq) analysis of cultured primary PDA cells reveals characteristics of embryonic progenitors of pancreatic ducts and endocrine cells, and extraordinarily high expression of the receptor tyrosine kinase Axl, an emerging cancer drug target. In proof-of-principle drugscreens, we find that we anling KIC mice with PDA treated for 2 weeks with gemcitabine (with or without Abraxane) plus inhibitors of Axl signaling (warfarin and BGB324) have fewer tumor initiation sites and reduced tumor size compared with the standard-of-care treatment. Rgs16::GFP is therefore an in vivo reporter of PDA progression and sensitivity to new chemotherapeutic drug regimens such as Axl-targeted agents. This screening strategy can potentially be applied to identify improved therapeutics for other cancers.

KW - Abraxane

KW - Axl

KW - Gas6

KW - Gemcitabine

KW - Kras

KW - Pancreatic cancer combination therapy

KW - Rapid in vivo screen

KW - Rgs16::GFP reporter

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=84943425675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943425675&partnerID=8YFLogxK

U2 - 10.1242/dmm.020933

DO - 10.1242/dmm.020933

M3 - Article

C2 - 26438693

AN - SCOPUS:84943425675

VL - 8

SP - 1201

EP - 1211

JO - DMM Disease Models and Mechanisms

JF - DMM Disease Models and Mechanisms

SN - 1754-8403

IS - 10

ER -